Cartesian Current Ratio from 2010 to 2026
| RNAC Stock | 7.42 0.06 0.82% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 8.49 | Current Value 8.91 | Quarterly Volatility 3.08068615 |
Check Cartesian Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cartesian Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 0.0 or Selling General Administrative of 21.7 M, as well as many indicators such as Price To Sales Ratio of 13.03, Dividend Yield of 0.0 or Days Sales Outstanding of 8.94. Cartesian financial statements analysis is a perfect complement when working with Cartesian Therapeutics Valuation or Volatility modules.
Cartesian | Current Ratio | Build AI portfolio with Cartesian Stock |
Latest Cartesian Therapeutics' Current Ratio Growth Pattern
Below is the plot of the Current Ratio of Cartesian Therapeutics over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. Cartesian Therapeutics' Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cartesian Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.00 X | 10 Years Trend |
|
Current Ratio |
| Timeline |
Cartesian Current Ratio Regression Statistics
| Arithmetic Mean | 4.29 | |
| Geometric Mean | 3.34 | |
| Coefficient Of Variation | 71.84 | |
| Mean Deviation | 2.75 | |
| Median | 2.07 | |
| Standard Deviation | 3.08 | |
| Sample Variance | 9.49 | |
| Range | 8.2311 | |
| R-Value | 0.52 | |
| Mean Square Error | 7.35 | |
| R-Squared | 0.27 | |
| Significance | 0.03 | |
| Slope | 0.32 | |
| Total Sum of Squares | 151.85 |
Cartesian Current Ratio History
About Cartesian Therapeutics Financial Statements
Cartesian Therapeutics stakeholders use historical fundamental indicators, such as Cartesian Therapeutics' Current Ratio, to determine how well the company is positioned to perform in the future. Although Cartesian Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cartesian Therapeutics' assets and liabilities are reflected in the revenues and expenses on Cartesian Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cartesian Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 8.49 | 8.91 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cartesian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cartesian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cartesian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cartesian Therapeutics Stock:Check out the analysis of Cartesian Therapeutics Correlation against competitors. For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cartesian Therapeutics. If investors know Cartesian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cartesian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth 0.168 | Return On Assets |
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cartesian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cartesian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cartesian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.